» Articles » PMID: 30232279

Neutrophil Accumulation and NET Release Contribute to Thrombosis in HIT

Overview
Journal JCI Insight
Date 2018 Sep 21
PMID 30232279
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Heparin-induced thrombocytopenia (HIT) is an immune-mediated thrombocytopenic disorder associated with a severe prothrombotic state. We investigated whether neutrophils and neutrophil extracellular traps (NETs) contribute to the development of thrombosis in HIT. Using an endothelialized microfluidic system and a murine passive immunization model, we show that HIT induction leads to increased neutrophil adherence to venous endothelium. In HIT mice, endothelial adherence is enhanced immediately downstream of nascent venous thrombi, after which neutrophils undergo retrograde migration via a CXCR2-dependent mechanism to accumulate into the thrombi. Using a microfluidic system, we found that PF4 binds to NETs, leading them to become compact and DNase resistant. PF4-NET complexes selectively bind HIT antibodies, which further protect them from nuclease digestion. In HIT mice, inhibition of NET formation through Padi4 gene disruption or DNase treatment limited venous thrombus size. PAD4 inactivation did affect arterial thrombi or severity of thrombocytopenia in HIT. Thus, neutrophil activation contributes to the development of venous thrombosis in HIT by enhancing neutrophil-endothelial adhesion and neutrophil clot infiltration, where incorporated PF4-NET-HIT antibody complexes lead to thrombosis propagation. Inhibition of neutrophil endothelial adhesion, prevention of neutrophil chemokine-dependent recruitment of neutrophils to thrombi, or suppression of NET release should be explored as strategies to prevent venous thrombosis in HIT.

Citing Articles

Neutrophil extracellular traps in tumor metabolism and microenvironment.

Liu Z, Dou Y, Lu C, Han R, He Y Biomark Res. 2025; 13(1):12.

PMID: 39849606 PMC: 11756210. DOI: 10.1186/s40364-025-00731-z.


Platelet integrin αIIbβ3 plays a key role in a venous thrombogenesis mouse model.

Adair B, Field C, Alonso J, Xiong J, Deng S, Ahn H Nat Commun. 2024; 15(1):8612.

PMID: 39366965 PMC: 11452527. DOI: 10.1038/s41467-024-52869-3.


Emerging therapeutic strategies targeting extracellular histones for critical and inflammatory diseases: an updated narrative review.

Yang T, Peng J, Zhang Z, Chen Y, Liu Z, Jiang L Front Immunol. 2024; 15:1438984.

PMID: 39206200 PMC: 11349558. DOI: 10.3389/fimmu.2024.1438984.


NET-targeted nanoparticles for antithrombotic therapy in pregnancy.

Zhou Y, Xu L, Jin P, Li N, Chen X, Yang A iScience. 2024; 27(5):109823.

PMID: 38756418 PMC: 11097077. DOI: 10.1016/j.isci.2024.109823.


Vascular dysfunction in hemorrhagic viral fevers: opportunities for organotypic modeling.

Zarate-Sanchez E, George S, L Moya M, Robertson C Biofabrication. 2024; 16(3).

PMID: 38749416 PMC: 11151171. DOI: 10.1088/1758-5090/ad4c0b.


References
1.
Kelton J, Hursting M, Heddle N, Lewis B . Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. Blood Coagul Fibrinolysis. 2008; 19(6):471-5. DOI: 10.1097/MBC.0b013e3282a167cc. View

2.
Caudrillier A, Kessenbrock K, Gilliss B, Nguyen J, Marques M, Monestier M . Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012; 122(7):2661-71. PMC: 3386815. DOI: 10.1172/JCI61303. View

3.
Xiao Z, Visentin G, Dayananda K, Neelamegham S . Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood. 2008; 112(4):1091-100. PMC: 2515144. DOI: 10.1182/blood-2008-04-153288. View

4.
Brandt S, Krauel K, Jaax M, Renne T, Helm C, Hammerschmidt S . Polyphosphates form antigenic complexes with platelet factor 4 (PF4) and enhance PF4-binding to bacteria. Thromb Haemost. 2015; 114(6):1189-98. DOI: 10.1160/TH15-01-0062. View

5.
Zhou A, Winkler A, Emamifar A, Gartland B, Duncan A, Antun A . Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis?. Chest. 2012; 142(5):1175-1178. DOI: 10.1378/chest.11-2926. View